Novo Nordisk: Court Victory and Pill Approval Propel Recovery, Yet 2026 Revenue Slump Casts a Shadow

Novo Nordisk wins South Africa patent interdict, oral Wegovy approval, and strong pipeline data; faces revenue decline and data breach fallout.

Novo Nordisk has been handed a series of catalysts in quick succession — a landmark patent ruling in South Africa, the first European approval of an oral weight-loss pill, and positive clinical data from its pipeline. Yet beneath the upbeat headlines, the Danish drugmaker faces a contracting top line and the lingering fallout of a major data breach.

South Africa Sets a Precedent on Compounding Loopholes

The most immediate legal win came on 22 June, when the Gauteng High Court in South Africa issued an interim interdict against iDexis. The company is now barred from manufacturing, distributing, or marketing unauthorised semaglutide products — a direct challenge to Novo Nordisk’s Ozempic and Wegovy brands. Crucially, the court rejected iDexis’s argument that so-called pharmaceutical compounding exceptions extend to chemically similar substances; only the identical active ingredient qualifies. The injunction will remain in force until South Africa’s drug regulator SAHPRA concludes its own investigation.

The ruling sends a strong signal for patent enforcement in emerging markets, where copycat versions have proliferated. But the picture is less favourable elsewhere. In Russia, local manufacturers have been permitted to produce duplicates of Novo Nordisk’s active ingredients until 2027, while in Brazil, domestic firm EMS has already launched its own semaglutide version following the expiration of certain patents.

Oral Wegovy Gets a European Green Light

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to an oral formulation of Wegovy — the first such go-ahead in Europe. The decision was backed by phase?3 data from the OASIS 4 trial. Until now, Wegovy was available only as an injection; a pill significantly lowers the barrier for patient uptake and expands the addressable market. The market is now watching for a formal submission for the oral pill in China, expected in the coming months.

Pipeline Data Strengthen the Competitive Arsenal

Novo Nordisk also unveiled encouraging results for CagriSema, its combination of cagrilintide and semaglutide. Late-stage data showed a weight loss of 14.2% and an HbA1c reduction of two percentage points — figures that bolster the company’s position against rival Eli Lilly. Separately, fresh analyses presented at the European Congress on Obesity indicated that early responders to high-dose Wegovy achieved an average weight reduction of 27.7%, versus 15.4% among other patient subgroups.

Market Access and Capital Returns

On the commercial front, CVS Health expanded its GLP?1 support programmes. Medicare patients will now pay a maximum of $50 a month for Wegovy, and virtual weight?management consultations are available for $49, widening access to a key revenue driver.

Novo Nordisk has also been active in the secondary market. Between 15 and 19 June, it repurchased roughly 1.075 million B?shares for approximately 308 million Danish kroner. Since the buyback programme began in February 2026, the company has bought back more than 20.9 million shares at an average price of 266.09 DKK. Institutional ownership presents a mixed picture: Dodge & Cox increased its stake by 19.3 million shares in the first quarter, and Susquehanna added 9.9 million, while FMR LLC trimmed its position by 8.7 million shares.

Technical Bounce, but Fundamentals Flash Warnings

The shares changed hands at €40.84 on the day, a gain of nearly 2%, and have rallied 8.67% over the past seven days. The stock now trades comfortably above its 50?day moving average of €37.33, and the relative strength index of 66.7 points to strong momentum, though it is approaching overbought territory. Year?to?date, however, the stock remains 9% in the red and sits roughly 33% below its 52?week high of €61.20.

Berenberg raised its price target to 325 DKK and reaffirmed a buy rating. Yet the outlook is constrained by a forecast revenue and operating profit decline of 4% to 12% for the 2026 financial year. Adding to the uncertainty, a cyber?attack resulted in the theft of 1.1 terabytes of corporate data — a breach whose impact on institutional confidence will become clearer with the next quarterly report.

Foundation?Backed Research and the Next Catalyst

The Novo Nordisk Foundation is investing up to 450 million Danish kroner (around €60 million) over six years in a new research network called CardioMetabolic Bridge, linking laboratories in London, Italy, and Germany. The effort underscores the company’s long?term commitment to metabolic disease.

The immediate near?term catalyst for the stock is the second?quarter earnings release scheduled for 5 August 2026, which will test whether the commercial scaling of obesity products can offset the broader revenue headwinds.